Roquefort Therapeutics
Dr Darrin M Disley OBE is a prominent figure in biotechnology and investment, currently serving as a Non Executive Director at Roquefort Therapeutics plc, an Advisory Board Member at Sana Capital, and CEO of Mogrify, a company specializing in cell conversion technology. Dr Disley holds leadership roles including Chairman of the Board at Celixir, a regenerative medicine firm, and Principal & Founder of Carpe Diem Investment Fund, investing in IT, Tech, and Life Sciences. Previous contributions include roles as Chairman of Trustees at Footprint Cafes CIO, Honorary Visiting Fellow at The University of Salford, Honorary Fellow in Entrepreneurship at Cambridge Judge Business School, and Enterprise Fellow at the University of Cambridge. Dr Disley earned a PhD in Biotechnology from the University of Cambridge and holds a Doctor of Science (Honoris Causa) from The University of Salford.
This person is not in any teams
This person is not in any offices
Roquefort Therapeutics
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.